[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"dysphagia-esophageal\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:dysphagia-esophageal":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,39,64,91],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100401172","esophageal-impedance-and-manometry-measurements-and-dysphagia-symptom-scoring-100401172",false,"NCT04503785","Esophageal Impedance and Manometry Measurements and Dysphagia Symptom Scoring","Inclusion Criteria:\n\n* All patients who presented to GI Motility Lab at IU University Hospital for esophageal manometry-impedance and\u002For EndoFLIP\n\nExclusion Criteria:\n\n* Age \\\u003C18 yrs old\n* Unable to communicate verbally with the staff","ALL","18 Years","99 Years",{"count":19,"type":20},1000,"ESTIMATED","6 Months","OBSERVATIONAL","Comparison of manometry measurements and EndoFlip Balloon measurements in patients with dysphagia and a known esophageal diagnosis",[25],"Dysphagia, Esophageal","RECRUITING","2026-06-15",{"date":29,"type":30},"2026-06-16","ACTUAL",{"date":32,"type":30},"2017-01-17",{"date":34,"type":20},"2027-12-31",{"name":36,"class":37},"Indiana University","OTHER",1,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":46,"sex":15,"minAge":16,"maxAge":47,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":51,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":38},"100493725","striated-esophageal-motor-function-modulation-in-health-and-disease-100493725","NCT05708885","Striated Esophageal Motor Function Modulation in Health and Disease","Characterization of the Striated Esophagus (St.Eso) Deglutitive Motor Function and Its Modulation by Pharyngeal Phase Swallow Biomechanics","Inclusion Criteria:\n\n* Healthy subjects aged 18 to 90 years.\n* Patents with dysphagia but normal high resolution esophageal manometric findings defined by the Chicago classification.\n\nExclusion Criteria:\n\n* Anyone less than 18 years old.\n* Patients with recent head and neck cancer (\\\u003C1 month post-surgery or \\\u003C3 months post-chemo radiation.\n* Patients suffering from muscle diseases like muscular dystrophies, myopathies.\n* Patients with neuro-muscular junction disorders myasthenia gravis, Eaton-Lambert disorders.\n* Patients having history of allergy to lidocaine or barium.\n* Patients who are pregnant or lactating.\n* Patients who are medically unstable.\n* Patients who are unable to apply the exerciser independently or with the help of a caregiver.\n* Patients who lack cognition.",true,"90 Years",{"count":49,"type":20},557,"INTERVENTIONAL",[52],"NA","The investigators hypothesize that striated esophagus deglutitive motor function is modulated by pharyngeal phase swallowing biomechanics.",[25],"2026-04-29",{"date":57,"type":30},"2026-05-05",{"date":59,"type":30},"2022-09-13",{"date":61,"type":20},"2027-04",{"name":63,"class":37},"Medical College of Wisconsin",{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":72,"targetDuration":4,"studyType":50,"phases":74,"briefSummary":75,"conditions":76,"keywords":4,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":90},"100583125","per-oral-endoscopic-myotomy-poem-in-patients-with-postfundplication-dysphagia-100583125","NCT06872255","Per-oral Endoscopic Myotomy (POEM) in Patients with Postfundplication Dysphagia","A Prospective Pilot Trial of Per-oral Endoscopic Myotomy (POEM) in Patients with Postfundplication Dysphagia (VADYSMA Trial)","VADYSMA","Inclusion Criteria:\n\n1. Patients after laparoscopic fundoplication procedure by Nissen (total, 360°), Dor (anterior, 180°) or Toupet (posterior, 270°) for gastroesophageal reflux disease no later than 10 years before enrolment.\n2. Refractory (\\> 6 months) and severe dysphagia after fundoplication procedure defined as an Eckardt score ≥3 and Mellow - Pinkas score ≥2 at baseline.\n3. X-ray (contrasted radiographic examination of the esophagus) characterized by both: a.) tapered narrowing of the distal esophagus and GEJ; b.) partial\u002Ftotal stagnation of the contrast solution above the GEJ\n4. Endoluminal planimetry: EGJ-DI \\\u003C 3 mm2\u002FmmHg (with 40ml)\n5. Age above 18 years\n6. Signed informed consent form\n\nExclusion Criteria:\n\n1. No previous attempt with at least one prokinetic drug\n2. Previous esophageal myotomy (open, laparoscopic or endoscopic)\n3. Primary esophageal motility disorder (achalasia etc.)\n4. Active erosive esophagitis\n5. Active peptic ulcer disease\n6. Esophageal stricture (peptic, malignant, other)\n7. Partial or complete supradiaphragmatic migration of the wrap and\u002For stomach (Hinder Type III - IV), Large hiatal hernia more than 5 cm\n8. Known eosinophilic esophagitis\n9. Severe coagulopathy\n10. Esophageal or gastric varices\n11. Advanced liver cirrhosis (Child B or Child C)\n12. Pregnancy or puerperium\n13. Malignant or pre-malignant esophageal diseases (dysplasia): patients with a history of such disease after its cure are eligible for enrolment\n14. Any other condition, which in the opinion of the investigator would interfere with study requirements\n15. Known gastroparesis",{"count":73,"type":20},30,[52],"Laparoscopic fundoplication represents the standard antireflux procedure, when conservative measures fail. However, any type of fundoplication may be accompanied by adverse events. Postfundoplication dysphagia (PFD) may hamper results of anti-reflux surgery. Endoscopic pneumatic dilation has been considered as the first line treatment option for persistent PFD. However, studies have not confirmed its effectiveness in this indication. Peroral endoscopic myotomy (POEM) became a standard treatment for the management of esophageal achalasia and moreover has also been assessed in a small cohort of patients with refractory PFD and some patients achieved significant treatment success. We plan to perform a prospective international cohort multicenter study assessing the efficacy of POEM in patients with persistent and severe PFD.",[77,25,78],"Dysphagia","Healthy","NOT_YET_RECRUITING","2025-03-06",{"date":82,"type":30},"2025-03-12",{"date":84,"type":20},"2025-04-01",{"date":86,"type":20},"2027-06-01",{"name":88,"class":89},"Institute for Clinical and Experimental Medicine","OTHER_GOV",2,{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":4,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":98,"targetDuration":4,"studyType":50,"phases":100,"briefSummary":102,"conditions":103,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":38},"100487610","phase-4-buspirone-for-weak-or-absent-esophageal-peristalsis-100487610","NCT05629325","Buspirone for Weak or Absent Esophageal Peristalsis","The Effect of Oral Buspirone Hydrochloride on Esophageal Motility, Bolus Transit and Symptoms of Dysphagia, in Patients With Poor Esophageal Motility: A Randomized, Double-blind, Placebo Controlled, Cross-over Trial With HRiM","Inclusion Criteria:\n\nPatients can participate in this study if:\n\n1. A minimum of 18 years old;\n2. Ineffective Esophageal Motility (IEM) or absent contractility, as determined on HRM in the last three months before inclusion in the study, using the Chicago classification v4.0 (1).\n\n   IEM is defined as \\>70% ineffective or ≥50% failed swallows with a normal integrated relaxation pressure (IRP4). IEM includes a weak contraction (DCI ≥ 100 mmHg·s·cm and \\\u003C450 mmHg·s·cm), failed peristalsis (DCI \\\u003C 100 mmHg·s·cm), or fragmented peristalsis (a large break (\\>5 cm length) in the 20-mmHg isobaric contour with DCI \\> 450 mmHg·s·cm).\n\n   Absent contractility is defined as 100% failed swallows (DCI \\\u003C 100 mmHg·s·cm), with a normal IRP4.\n3. Have completed a gastro-duodenoscopy, within 12 months, showing no anatomical abnormality of the stomach or esophagus, which can explain the patients' symptoms.\n4. History of dysphagia for at least 2 months, at least twice per week in the last month.\n5. Sexually active women of childbearing potential participating in the study must be using an appropriate form of contraception. Medically acceptable forms of contraception include oral contraceptives, injectable or implantable methods, intrauterine devices, or properly used barrier contraception. If the female patient has not been on oral, injectable, implantable or intrauterine contraception, a urinary pregnancy test will be performed prior to administration of Buspirone\u002FPlacebo.\n6. Subjects must be capable of understanding and be willing to provide signed and dated written voluntary informed consent before any protocol-specific screening procedures are performed.\n\nExclusion Criteria:\n\nPatients cannot participate in this study if:\n\n1. Endoscopic signs of severe erosive esophagitis (grade C or D, Los Angeles classification) on endoscopy performed off PPI treatment in the 12 months prior to screening, or ≥ grade B when endoscopy is performed during PPI treatment.\n2. Systemic diseases, known to affect esophageal motility (i.e. systemic sclerosis)\n3. Surgery in the thorax or in the upper part of the abdomen (appendectomy and cholecystectomy are allowed).\n4. Hiatal hernia ≥3 cm\n5. QT c\\>450 ms.\n6. Use of medication that effect cholinergic function such as anticholinergics, tricyclic antidepressants.\n7. Concomitant promotility agents such as prucalopride or domperidone.\n8. Concomitant use of more than one benzodiazepine.\n9. Significant neurological, respiratory, hepatic, renal, hematological, cardiovascular, metabolic or gastrointestinal cerebrovascular disease as judged by the investigator.\n10. Major psychiatric disorder.\n11. Pregnancy or breastfeeding.\n12. History of poor compliance.\n13. History of\u002For current psychiatric illness that would interfere with ability to comply with protocol requirements or give informed consent.\n14. History of alcohol or drug abuse that would interfere with ability to comply with protocol requirements.",{"count":99,"type":20},25,[101],"PHASE4","This is a randomized, double-blind, placebo-controlled, cross-over clinical trial of buspirone in patients with complaints of dysphagia due to poor esophageal motility. The goal of this clinical trial is to study the effect of buspirone on esophageal motility by performing high resolution impedance manometry (HRiM).",[25],"2024-07-01",{"date":106,"type":30},"2024-07-03",{"date":108,"type":30},"2021-07-06",{"date":110,"type":20},"2024-09-30",{"name":112,"class":37},"Universitaire Ziekenhuizen KU Leuven"]